$TWST

Finn Patrick John sold $210K of TWST

Finn Patrick John (President and COO) sold 2,238 shares of Twist Bioscience Corp (TWST) at $93.89 ($0.21M total) on 2026-07-23.

Original reporting
SEC EDGAR · Finn Patrick John
Published Jul 27, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 27, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates the insider’s holdings but does not provide new information about Twist’s business performance, pipeline, or financial guidance.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing without additional company-specific catalysts.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on prior sales or compensation, directional inference is weak.

Relevance 4/10Novelty 2/10Timing: Filed 2026-07-27, transaction dated 2026-07-23.

Background

This is an SEC Form 4 insider transaction disclosure for Twist Bioscience, reported by its President and COO.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Form 4 shows Twist Bioscience COO Finn Patrick John sold 2,238 shares for about $210K at $93.8930 on 2026-07-23.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4 sale.

Evidence & confidence

The filing is an insider transaction, not a company disclosure like earnings, guidance, or a deal. The article provides sale size and price but no new operational or financial information.

Market effects

Minimal. Insider selling in a single biotech tool/tech name does not materially change sector fundamentals.

Minimal, US-focused filing with no broader macro/regional linkage.

Minimal, no international transaction or regulatory action described.

Counterpoint

If the market interprets the absence of a disclosed 10b5-1 plan as discretionary selling, it could create short-term negative sentiment despite the modest dollar amount.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Finn Patrick John

    President and COO who sold 2,238 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.